Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bugat

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|January 1, 1997
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell linesM J Caliaro, P Vitaux, C Lafon, et al.
Bulletin Du Cancer|December 14, 2001
[Cost-effectiveness in diagnosis and treatment of carcinomas of unknown primary origin]K Desboeuf, L Molinier, M O Carrère, et al.
British Journal of Cancer|July 17, 1999
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissuesS Guichard, C Terret, I Hennebelle, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1995
CPT-11 (irinotecan) in the treatment of colorectal cancerJ P Armand, M Ducreux, M Mahjoubi, et al.
Bulletin Du Cancer|May 1, 1993
[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]M de Forni, V Gualano, P Canal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studiesE Chatelut, M de Forni, P Canal, et al.
Bulletin Du Cancer|November 1, 1995
[Prediction of carboplatin clearance from morphological and biological patient characteristics]E Chatelut, A Dezeuze, M Lavit, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineF Lokiec, P Canal, C Gay, et al.
Cancer Research|October 15, 1993
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomasP Canal, M Attal, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Population pharmacokinetics of total and unbound etoposideL Nguyen, E Chatelut, C Chevreau, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|January 1, 1997
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell linesM J Caliaro, P Vitaux, C Lafon, et al.
Bulletin Du Cancer|December 14, 2001
[Cost-effectiveness in diagnosis and treatment of carcinomas of unknown primary origin]K Desboeuf, L Molinier, M O Carrère, et al.
British Journal of Cancer|July 17, 1999
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissuesS Guichard, C Terret, I Hennebelle, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1995
CPT-11 (irinotecan) in the treatment of colorectal cancerJ P Armand, M Ducreux, M Mahjoubi, et al.
Bulletin Du Cancer|May 1, 1993
[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]M de Forni, V Gualano, P Canal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studiesE Chatelut, M de Forni, P Canal, et al.
Bulletin Du Cancer|November 1, 1995
[Prediction of carboplatin clearance from morphological and biological patient characteristics]E Chatelut, A Dezeuze, M Lavit, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineF Lokiec, P Canal, C Gay, et al.
Cancer Research|October 15, 1993
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomasP Canal, M Attal, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Population pharmacokinetics of total and unbound etoposideL Nguyen, E Chatelut, C Chevreau, et al.
Pageof 15